IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 701–800 of 1,000
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
Chae, Y. J., Lee, K.-G., Oh, D., Lee, S., Park, Y., & Kim, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400235 · Cited by 11
Fukuda, M., Kusama, K., & Sakashita, H. (2011) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2011.08.001 · Cited by 14
“rendering a protective effect against chemically induced carcinogenesis [146].”
Backgroundvan Geemen, D., Vis, P. W. R., Soekhradj-Soechit, S., Sluijter, J. P. G., Beest, M. D. L.-V., Kluin, J., & Bouten, C. V. C. (2011) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2010.0556 · Cited by 11
Lönneborg, A., Aarøe, J., Dumeaux, V., & Børresen‐Dale, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.31 · Cited by 11
Palma, L., Sfara, C., Antonelli, A., & Magnani, M. (2011) · BMC Pharmacology · doi:10.1186/1471-2210-11-8 · Cited by 12
“Moreover, the IL-23/IL-17 axis plays a role during inflammatory process-derived tumor development: IL-23 decreases number and activity of cytotoxic T cells in transformed tissues [20].”
BackgroundA novel strategy by cryoablation for advanced hepatoma.
Osada, S., Yoshida, K., & Saji, S. (2009) · PubMed · Cited by 11
The Effects of Anti-IL-23p19 Therapy on Atherosclerosis Development in ApoE −/− Mice
Wang, J., Zhao, P., Gao, Y., Zhang, F., Yuan, X., Jiao, Y., & Gong, K. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0050 · Cited by 11
The Dog as a Model to Study the Tumor Microenvironment
Carvalho, M. I., Raposo, T. P., Silva-Carvalho, R., Pires, I. C. R., Prada, J., Gregório, H., & QUEIROGA, F. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_7 · Cited by 13
Expression of interleukin-23 and its receptors in human squamous cell carcinoma of the oral cavity
Fukuda (2009) · Molecular Medicine Reports · doi:10.3892/mmr_00000223 · Cited by 11
Gene expression changes in human islets exposed to type 1 diabetic serum
Jackson, A. M., Kanak, M. A., Grishman, E. K., Chaussabel, D., Levy, M. F., & Naziruddin, B. (2012) · Islets · doi:10.4161/isl.21510 · Cited by 11
Simpson-Abelson, M. R., & Bankert, R. B. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.477 · Cited by 12
“showed, using a chemical carcinogenesis model, that mice lacking the ability to respond to IL-23 were completely resistant to tumor formation [100] .”
Combined Effect of IL-12Rβ2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer
Tao, Y., Tao, T., Gross, N. D., Peng, X., Li, Y., Huang, Z., Liu, L., Li, G., Chen, X., & Yang, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494515 · Cited by 11
Strategies of the War on Cancer: To Kill or to Neutralize?
Lichtenstein, A. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00667 · Cited by 11
“There are a number of interesting examples of using a similar anticancer strategy in experimental mouse models: (i) oral administration of soda solution neutralizes intratumor acidity and suppresses tumor growth (68, 69); (ii) antibodies to interleukin-23 raise the immune response (70); (iii) sympathectomy blocks pros…”
BackgroundLethal-7-related polymorphisms are associated with susceptibility to and prognosis of gastric cancer
Jia, Z., Cao, D., Wu, Y., Jin, M., Pan, Y.-C., Cao, X., & Jiang, J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i8.1012 · Cited by 11
Matsui, M. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00249.x · Cited by 11
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3
Quatromoni, J. G., Morris, L. F., Donahue, T. R., Wang, Y., McBride, W. H., Chatila, T. A., & Economou, J. S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-48 · Cited by 12
“A number of additional chemokines and cytokines are implicated in Treg proliferation or induction, including IFNg, IL-6, IL-23, IL-21, Cox2, and indolamine 2,3 dioxygenase [22,23,42-45].”
BackgroundThe effects of indoprofen vs paracetamol on swelling, pain and other events after surgery.
Olstad, O. A., & Skjelbred, P. (1986) · PubMed · Cited by 13
(2011) · Springer eBooks · doi:10.1007/springerreference_32754 · Cited by 11
Nayak, D. A., Sedlacek, A. L., Cillo, A. R., Watkins, S. C., & Binder, R. J. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0326 · Cited by 10
TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid
Tabatabaei‐Panah, P., Moravvej, H., Aghaei, S., Akbari, M., Rajabi, S., Kia, A., Ebrahimi, E., Sadaf, Z., Atoon, A., Behravesh, N., et al. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1519 · Cited by 11
“It is also shown that mice deficient for IL-23 or IL-23 receptor are partially resistant to develop experimental models of auto-inflammatory diseases, suggesting a significant influence of IL-23 in the inflammatory process (Cua et al., 2003; Kikly et al., 2006; Langowski et al., 2006; Murphy et al., 2003).”
BackgroundEmerging immunologic approaches as cancer anti-angiogenic therapies
Azimi, M., Manavi, M. S., Afshinpour, M., Khorram, R., Vafadar, R., Rezaei‐Tazangi, F., Arabzadeh, D., Arabzadeh, S., Ebrahimi, N., & Aref, A. R. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03667-2 · Cited by 10
“Stromal cell-derived factor 1 (SDF-1) Recruitment and retention of CXCR4 + BM cells to the neo-angiogenic niches [78] and neck cancers [89, 90].”
Eslami, S. M., & Lü, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.035 · Cited by 10
Carcinogenesis: Evolution of concepts
Lichtenstein, A. V. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909040014 · Cited by 11
Shapiro, M., Nandi, B., Pai, C., Samur, M., Pelluru, D., Fulciniti, M., PRABHALA, R. H., Munshi, N. C., & Gold, J. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1769-2 · Cited by 10
Stüssi‐Helbling, M., Lukesch, A. C., Haimovici, A., Karamitopoulou, E., Berger, M. D., Hädrich, M., Mallaev, M., Schnüriger, B., Koelzer, V. H., Dawson, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2069 · Cited by 10
“In vivo studies also support the pro-tumour effect of IL-23 and its receptor as underlined by work on knock-out mice (IL-23R-/- or IL-23p19-/-) showing marked growth-restriction in transplanted tumours and reductions in angiogenesis [8-10].”
BackgroundMethodResultInfluentialLi, Z., Zhang, X., Liu, C., & Ma, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.729941 · Cited by 12
Self-citationBackman, S. A., Kollara, A., Haw, R., Stein, L. D., & Brown, T. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097997 · Cited by 10
“In contrast to IL12, IL23 promotes pro-inflammatory responses and diminishes tumor infiltration of cytotoxic T cells as determined in a DMBA/TPA-induced skin papilloma mouse model [65].”
BackgroundThe Plasmodium Circumsporozoite Protein, a Novel NF-κB Inhibitor, Suppresses the Growth of SW480
Ding, Y. P., Huang, X., Liu, T., Fu, Y., Tan, Z., Zheng, H., Zhou, T., Dai, J., & Xu, W. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9519-7 · Cited by 10
“During tumor progression, infiltrating immune cells consisting mainly of tumor-associated macrophages (TAMs), activate the NF-κB of cancer cells through the secretion of proinflammatory cytokines (TNF-α, IL-1, IL-6 or IL-23) [9, 10].”
BackgroundRetractedPoniewierska-Baran, A., Tokarz–Deptuła, B., & Deptuła, W. (2021) · Archives of Medical Science · doi:10.5114/aoms.2019.89835 · Cited by 10
Okumura, K., Saito, M., Yoshizawa, Y., Ito, Y., Isogai, E., Araki, K., & Wakabayashi, Y. (2020) · Oncogene · doi:10.1038/s41388-020-1323-3 · Cited by 10
IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer.
Khodadadi, A., Razmkhah, M., Eskandari, A., Hosseini, A., Habibagahi, M., Ghaderi, A. A., & Jaberipour, M. (2014) · PubMed Central · Cited by 9
Bizzini, B., Drouet, B., Zagury, D., Abitbol, M. M., Burny, A., & Boissier, M. (2010) · Immunotherapy · doi:10.2217/imt.10.16 · Cited by 10
Post-transplant adoptive T-cell immunotherapy
Aqui, N. A., & June, C. H. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.001 · Cited by 11
Pappu, B. P., & Dong, C. (2007) · Current Protocols in Immunology · doi:10.1002/0471142735.im0625s79 · Cited by 10
“Moreover, elevated levels of IL-17 expression have been associated with several autoimmune and inflammatory diseases (Tartour et al., 1999; Iwakura and Ishigame, 2006; Langowski et al., 2006; Weaver et al., 2006).”
BackgroundPsoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment
Bruni, M., Lobefaro, F., Pellegrini, C., Mastrangelo, M., Gualdi, G., Esposito, M., Antonetti, P., Sanctis, P. D., Amerio, P., & Fargnoli, M. C. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2471093 · Cited by 13
“The influence of IL-23 as protumoral or antitumoral cytokine independently of the IL-17/Th17 pathway is still debated [35–37] In the early phase of carcinogenesis, IL-23 was shown to inhibit immune surveillance by preventing the infiltration of cytotoxic CD8+T cells [35].”
Huang, Z. J., Bu, D., Yang, N., Huang, W., Zhang, L., Li, X., & Ding, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1180402 · Cited by 13
“Il12b-expressing DCs identified in this study are found relating to lung metastasis and IL12B can associate with IL23A to form the IL-23 interleukin, which leads to the generation of IL-17-producing CD4 T cells and is important for tumorigenesis (34).”
BackgroundA novel chip-based parallel transfection assay to evaluate paracrine cell interactions
Kuhn, E., Naschberger, E., Konrad, A., Croner, R. S., Britzen‐Laurent, N., Jochmann, R., Münstedt, H., & Stürzl, M. (2012) · Lab on a Chip · doi:10.1039/c2lc20724a · Cited by 9
Helicobacter Pylori HP0175 Promotes the Production of IL-23, IL-6, IL-1β and TGF-β
Amedei, A., Munari, F., Bella, C. D., Niccolai, E., Benagiano, M., Bencini, L., Cianchi, F., Silvestri, E., D’Elios, S., Farsi, M., et al. (2013) · European Journal of Inflammation · doi:10.1177/1721727x1301100127 · Cited by 9
Jin, B., Zhang, Y., Miller, H. D., He, L., Ge, D., Wang, A. R., & You, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10081976 · Cited by 9
“The proliferative signaling of keratinocytes is initiated by IL17 through recruitment of IL-17RA/IL-17RC and then Act1, which is assumed to explain the link between psoriasis and skin tumorigenesis [10,40,41].”
BackgroundDeepak, P., & Acharya, A. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.483027 · Cited by 10
“MMP9 production [206] Anti-inflammatory cytokines”
BackgroundFang, S., Wang, Y., Chun, Y. S., Liu, H., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., Schacherer, C. W., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.138 · Cited by 11
“In contrast, IL-23 contributes to autoimmune inflammation (Langrish et al., 2004) and stimulates tumor growth through the induction of tumor-promoting microenvironments (Langowski et al., 2006).”
BackgroundTherapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
Szudy‐Szczyrek, A., Ahern, S., Kozioł, M., Majowicz, D., Szczyrek, M., Krawczyk, J., & Hus, M. (2021) · Cancers · doi:10.3390/cancers13194806 · Cited by 9
Abe, T., Fuse, I., Narita, M., Takahashi, M., & Aizawa, Y. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03911.x · Cited by 9
Tumor Microenvironment and the Immune Response
Selleri, S., Rumio, C., Sabatino, M., Marincola, F. M., & Wang, E. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.002 · Cited by 9
Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice
Zhong, Z., Zhai, Y., Bu, P., Shah, S., & Qiao, L. (2017) · Nature Communications · doi:10.1038/ncomms15004 · Cited by 10
Innate lymphoid cells in antitumor immunity
Salomé, B., & Jandus, C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0617-266r · Cited by 9
Jin, H.-T., Youn, J. Y., Choi, S.-Y., Seo, S.-H., Park, S.-H., Song, M.-Y., Yang, S.-H., & Sung, Y.-C. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.41 · Cited by 9
“9 On the other hand, it has been reported that the expression of IL-23 was increased in a human tumor and the growth of the transplanted tumor was restricted in hosts depleted for IL-23 or IL-23R, indicating the role of IL-23 in promoting tumor incidence and growth”
BackgroundPrins, R., Fernandez, D. J., Akbari, O., Silva, D. M. D., & Kast, W. M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011915 · Cited by 10
Lee, L. S., Bellizzi, A. M., Banks, P. A., Sainani, N. I., Kadiyala, V., Suleiman, S., Conwell, D. L., & Paulo, J. A. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/247309 · Cited by 8
Considerations of the Genetic Background of Obesity among Patients with Psoriasis
Czarnecka, A., Purzycka-Bohdan, D., Zabłotna, M., Bohdan, M., Nowicki, R. J., & Szczerkowska‐Dobosz, A. (2023) · Genes · doi:10.3390/genes14030594 · Cited by 9
“These findings implicate the IL12B gene in the pathogenesis of autoimmune inflammatory disorders such as psoriasis [79].”
BackgroundTriggering Tumor Immunity through Angiogenesis Targeting
Jinushi, M., & Dranoff, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0880 · Cited by 9
Malyshev, I. Y., Manukhina, E. B., & Malyshev, Y. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.03.019 · Cited by 14
Herek, T. A., Shew, T. D., Spurgin, H. N., & Cutucache, C. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142682 · Cited by 8
“IL23 is an immunomodulatory cytokine with controversial findings in terms of its anti-tumor properties [66, 67].”
BackgroundExpression of Serum IL-22, IL-23, and TLR9 as Tumor Markers in Untreated Breast Cancer Patients
Abdullah, H. N., & Abdulwahid, A. G. (2020) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.10.3.30 · Cited by 8
Smeets, F. G. M., Liedorp, P. R., van der Poel, M., Miclea, R. L., Masclee, A., & Pierik, M. J. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz084 · Cited by 8
The Role of Cytokines, Chemokines and NFkB in Inflammation and Cancer
(2023) · Journal of Case Reports and Medical History · doi:10.54289/jcrmh2300114 · Cited by 19
Almanza, G., Searles, S. C., & Zanetti, M. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.64 · Cited by 9
“In the TME, macrophages display a mixed phenotype characterized by the upregulation of pro-inflammatory cytokines such as IL-6 [28] and IL-23 [29] , but also the immune suppressive factor Arginase 1, which restricts T cell function [30] .”
BackgroundBarnet, M. B., Jackson, K., Masle‐Farquhar, E., Russell, A., Burnett, D. L., Chye, A., Jara, C., Faulks, M. L., Mawson, A., Peters, T. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314258122 · Cited by 8
Does p40‐targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths, C. E. M., & Girolomoni, G. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04604.x · Cited by 7
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors
Wilczyński, J. R., & Nowak, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_8 · Cited by 9
Santostefano, M. J., Herzyk, D., Montgomery, D. L., & Wolf, J. J. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104476 · Cited by 7
Pérez‐Torres, A., Vera-Aguilera, J., Sahaza, J. H., Vera-Aguilera, C., Moreno-Aguilera, E., Pulido‐Camarillo, E., Ochoa, L. N., & Jeganathan, P. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2015.1835 · Cited by 7
“62 However, IL-23 could also have pro-tumoral effects as demonstrated by Teng (2013); IL-23 suppresses innate antitumor responses, NK cell perforin, and IFN-c effector functions, and suppression is independent of host IL-17A.”
Pencovich, N., Hantisteanu, S., Wurtzel, O., Hallak, M., & Fainaru, O. (2013) · Genes and Immunity · doi:10.1038/gene.2012.59 · Cited by 7
Potential role of ustekinumab in the treatment of chronic plaque psoriasis
Naldi, L. (2010) · Biologics · doi:10.2147/btt.s4921 · Cited by 7
“On the other hand, IL-23p19-deficient mice have a strong resistance to tumor challenge.(60) The relevance of these findings for malignancy risk in humans treated by ustekinumab is unknown.”
Potential Avenues for Immunotherapy of Colitis-Associated Neoplasia
Waldner, M. J., & Neurath, M. F. (2012) · Immunotherapy · doi:10.2217/imt.12.15 · Cited by 7
Relationship between Cancer and Cytokines
Kabel, A. M. (2014) · doi:10.12691/jcrt-2-2-3 · Cited by 7
Elevated levels of interleukin-23 in sera of patients with pemphigus vulgaris.
Pouralibaba, F., Babaloo, Z., Pakdel, F., Abdollahian, T., & Mehrbani, S. P. (2012) · PubMed · doi:10.22034/iji.2012.16880 · Cited by 7
Wang, P., Zhang, Y., Zhang, J., Jiang, J., Jin, F., & Sun, Z. (2018) · Oncology Reports · doi:10.3892/or.2018.6775 · Cited by 9
The relationship between blood IL ‐12p40 level and melanoma progression
Fang, S., Wang, Y., Chun, Y. S., Liu, H., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., Schacherer, C. W., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29182 · Cited by 7
“IL-23, conversely, contributes to autoimmune inflammation(7) and stimulates tumor growth and progression by providing a tumor-promoting microenvironment.(8) Thus, these cytokines can mediate host responses to tumors; however, their clinical importance in melanoma development and progression has not been determined.”
BackgroundParticipation of Brahmi (Bacopa monnieri L.) plant in regulation of cancer
Roy, S., Rakshit, S., Shanmugam, G., & Sarkar, K. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.03.017 · Cited by 8
ICOStomizing Immunotherapies with T H 17
Garaude, J., & Blander, J. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001722 · Cited by 6
“In sharp contrast to the studies mentioned above, other published data suggest that IL23 secreted by tumor-associated macrophages and IL-17 are tumor-promoting cytokines (39, 40).”
ResultSignaling new therapeutic opportunities: cytokines in prostate cancer
Chandran, E. B. A., Meininger, L., Karzai, F. H., & Madan, R. A. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2108701 · Cited by 7
Melanoma risk during immunomodulating treatment
Zheng, Y. J., Ho, W. W.-S., Sanlorenzo, M., Vujic, I., DAUD, A. I., Algazi, A. P., Rappersberger, K., & Ortiz‐Urda, S. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000838 · Cited by 7
Animal Models for Basic and Preclinical Research in Bladder Cancer
Mara, A., Lodillinsky, C., & Omar, E. F. (2012) · InTech eBooks · doi:10.5772/28580 · Cited by 6
“…(IFNɣ -/-), interleukins 17, 12 and 23 (IL-17 -/-; IL-12-/- and IL-23 -/-), among others, are being used to understand how different components of the immune system either promote or inhibit the development of bladder tumors (Kortylewski et al., 2009; Langowski et al., 2006; Wang et al., 2009).”
BackgroundRole of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Murugaiyan, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_7 · Cited by 8
“The absence of tumor formation in these mice correlated with the absence of various markers including IL-17, GR-1+, and CD11b+ myeloid cells which are indicative of tumorassociated infl ammation [ 196 ].”
BackgroundTargeting the IL-12/IL-23 axis
Smyth, M. J., & Teng, M. W. L. (2014) · OncoImmunology · doi:10.4161/onci.28964 · Cited by 6
Role of T-helper 17 cell related cytokines in laryngeal cancer
Müderris, T., Gül, F., Doblan, A., Ergin, M., & Müderris, T. (2019) · The Journal of Laryngology & Otology · doi:10.1017/s0022215119000689 · Cited by 6
Yeung, O. W. H., Xiang, Q., Pang, L., Liu, H., Ng, T., Liu, J., Lo, C. M., & Man, K. (2021) · Cancers · doi:10.3390/cancers13071503 · Cited by 6
Ondondo, B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00090 · Cited by 6
“Since Treg are a source of both IL-10 and TGF-β, the key cytokines in immuno-regulation, it is plausible that IL-23-driven loss of Treg contributes significantly to immune dysregulation by overriding the immunosuppressive pathways in the intestine and favoring IBD and CRC development via generation of pathogenic Th17…”
BackgroundInfluentialThe Contribution of Interleukin-12A Genotypes to Oral Cancer Risk in Taiwanese
Li, C.-H., Shih, L., Hsu, C.-L., Lee, H., WANG, Y.-C., CHANG, W.-S., Tsai, C.-W., Li, C., & Bau, D. (2020) · Anticancer Research · doi:10.21873/anticanres.14359 · Cited by 7
The Cellular Microenvironment and Metastases
Rankin, E. B., Erler, J. T., & Giaccia, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00003-5 · Cited by 9
Kaiser, K. M., Raabe, J., ToVinh, M., Hack, G., Ahmad, S., Müller, N., Cassella, J., Walravens, S. I., Alfaro, P., Garcia, L. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58907-y · Cited by 5
“This was an interesting observation as levels of IL-23 and its receptor chains have been shown to be elevated in numerous human cancers, including CRC, and to correlate with disease progression 38 .”
Interleukin-23 biology linking mucosal immunity to autoimmune diseases and cancer
Ahmed, A., & Sonnenberg, G. F. (2026) · Trends in Immunology · doi:10.1016/j.it.2025.12.005 · Cited by 6
Early detection and intervention in dermatomyositis: current evidence and clinical implications
Treasure, K., Chugh, R., Abbas, H., & Patel, A. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-07971-w · Cited by 5
“Increased levels of cytokines, arachidonic acid metabolites, chemokines, and reactive oxygen species may damage DNA and promote genetic mutations linked to cancer [51–53].”
Contribution of Interleukin-12A Genotypes to Breast Cancer Risk
WANG, Y.-C., Wang, Z., Shen, T., CHANG, W.-S., HUANG, S.-Z., Yu, C.-C., Chen, J., HSIAU, Y.-C., Yang, J., Tsai, C.-W., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15243 · Cited by 6
Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Garo, L. P., & Murugaiyan, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_13 · Cited by 6
Matuszczak, S., Szczepanik, K., Grządziel, A., Drzyzga, A., Cichoń, T., Czapla, J., Pilny, E., & Smolarczyk, R. (2023) · Biomedicines · doi:10.3390/biomedicines11061773 · Cited by 5
XU, L., YANG, G., Song, B., Chen, D., Yunus, A., Chen, J., YANG, X., & Tian, Z. (2023) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2666 · Cited by 6
“IL-23 was reported to promote tumor incidence and growth (Langowski et al., 2006).”
BackgroundRisankizumab in the Management of Psoriasis in Solid Organ Transplant Recipients
Luz, M., Lé, A. M., & Torres, T. (2024) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.09.023 · Cited by 5
Subversion and Coercion: The Art of Redirecting Tumor Immune Surveillance
Mumm, J. B., & Oft, M. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_47 · Cited by 5
“In contrast, deficiency in IL-23 or the IL-23 receptor dramatically reduces tumor incidence, and profoundly reduces established tumor growth (Langowski et al. 2006).”
BackgroundSelf-citationMolecular links between inflammation and cancer
Allavena, P., Germano, G., & Mantovani, A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.018 · Cited by 6
Dibra, D., Mitra, A., Newman, M., Xia, X., Keenan, C., Cutrera, J. J., Mathis, J. M., Wang, X., Myers, J. N., & Li, S. (2016) · Oncotarget · doi:10.18632/oncotarget.12581 · Cited by 5
“Interleukin (IL) 23 promotes epithelial carcinogenesis by reducing CD8 T cell infiltration [2].”
BackgroundChou, Y.-J., Wu, C., Pan, T., Wu, C., & Chang, Y.-T. (2022) · Dermatologic Therapy · doi:10.1111/dth.15804 · Cited by 5
“Preclinical studies in murine models revealed that interkeukin12/23 inhibition may be associated with a theoretical risk of tumor promotion.(31) Therefore, monitoring the malignancy risk in patients administered these targeted biologics for psoriasis remains a priority.”
BackgroundThe Role of Tumor Microenvironment in Oral Cancer
Fukuda, M., Ohmori, Y., & Sakashit, H. (2012) · InTech eBooks · doi:10.5772/33020 · Cited by 7
“IL-23, a heterodimeric cytokine with many similarities to IL-12, has recently been identified as a factor linking tumor-associated inflammation and a lack of tumor immune surveillance (Langowski et al., 2006).”
BackgroundWhat can rheumatologists learn from translational cancer therapy?
Sherlock, J. P., Filer, A. D., Isaacs, J. D., & Buckley, C. D. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4203 · Cited by 5
Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma
Ramoner, R. E., Rahm, A., Falkensammer, C. E., Leonhartsberger, N., & Thurnher, M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0827-z · Cited by 5
“Moreover, IL-23 stimulated angiogenesis and antagonized IL-12 and IFN- , both of which are crucial eVector cytokines of antitumor immune responses [28, 29].”
BackgroundLi, C.-H., Sun, K.-T., LI, X., Shih, L., Chen, L.-Y., Yu, C.-C., WANG, Y.-C., CHANG, W.-S., Tsai, C.-W., Li, C., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13866 · Cited by 5
A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis
Charakopoulos, E., Spyrou, I., Viniou, N., Giannakopoulou, N., Chatzidavid, S., & Diamantopoulos, P. T. (2020) · Medicine · doi:10.1097/md.0000000000020048 · Cited by 5
“2 Despite the fact that the simultaneous blockade of the IL-12 and IL-23 pathway is oncogenic in experimental animal models,([22,23]) the safety and efficacy of ustekinumab in the treatment of psoriasis has been well demonstrated in 3 phase III clinical trials: PHOENIX 1,([8]) PHOENIX 2,([24]) and ACCEPT.”
BackgroundA study on anti-tumor immunity induced by gene-modified melanoma B16 cells
Ge, S., Qian, G., Lu, J., Li, Q., Wang, K., Liu, X., Zhang, L., Zhang, X., & Fang, L. (2008) · Oncology Reports · doi:10.3892/or.19.6.1589 · Cited by 5
Self-citationSlavica, L., Nurkkala, M., Karlson, T. D. L., Ingelsten, M., Nyström, J., & Eriksson, K. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02713.x · Cited by 5
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.